Asian Pacific journal of allergy and immunology最新文献

{"title":"Phenotype characterization and biomarker evaluation in moderate to severe type 2-high asthma.","authors":"Sahoko Imoto, Maho Suzukawa, Yuma Fukutomi, Nobuyuki Kobayashi, Masami Taniguchi, Takahide Nagase, Ken Ohta","doi":"10.12932/AP-021222-1510","DOIUrl":"10.12932/AP-021222-1510","url":null,"abstract":"<p><strong>Background: </strong>There are two major pathological phenotypes of asthma, type 2 (T2)-high and T2-low asthma, which are important in determining treatment strategies. However, the characteristics and phenotypes of T2-high asthma have not yet been fully identified.</p><p><strong>Objective: </strong>This study aimed to identify the clinical characteristics and phenotypes of patients with T2-high asthma.</p><p><strong>Methods: </strong>This study used data from a nationwide asthma cohort study in Japan, NHOM Asthma Study. T2-high asthma was defined as a blood eosinophils count ≥ 300 /μL and/or fractional exhaled nitric oxide level ≥ 25 ppb, and the clinical characteristics and biomarkers were compared between T2-high and T2-low asthma. Furthermore, T2-high asthma was phenotyped via hierarchical cluster analysis using Ward's method.</p><p><strong>Results: </strong>Patients with T2-high asthma were older, less likely to be female, had longer asthma duration, had lower pulmonary function, and had more comorbidities, including sinusitis and SAS. Patients with T2-high asthma showed higher serum thymus and activation-regulated chemokine and urinary leukotriene E4 levels and lower serum ST2 levels than those with T2-low asthma. There were four phenotypes among patients with T2-high asthma: Cluster 1 (youngest, early-onset, and atopic), Cluster 2 (long duration, eosinophilic, and low lung function), Cluster 3 (elderly, female-dominant, and late-onset), and Cluster 4 (elderly, late-onset, and asthma-COPD overlap-dominant).</p><p><strong>Conclusions: </strong>Patients with T2-high asthma have distinct characteristics and four distinct phenotypes, in which eosinophil-dominant Cluster 2 is the most severe phenotype. The present findings may be useful in precision medicine for asthma treatment in the future.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"254-265"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9986738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between MTHFR polymorphism, dietary methyl donors, and childhood asthma and atopy.","authors":"Yean Jung Choi, So-Yeon Lee, Sung-Ok Kwon, Mi-Jin Kang, Ju-Hee Seo, Jisun Yoon, Hyun-Ju Cho, Sungsu Jung, Soo-Jong Hong","doi":"10.12932/AP-300422-1375","DOIUrl":"10.12932/AP-300422-1375","url":null,"abstract":"<p><strong>Background: </strong>Studies investigating the genetic association of the C677T methylenetetrahydrofolate reductase (MTHFR) genotype and dietary methyl donors with asthma and atopy are limited, and have variable results.</p><p><strong>Objective: </strong>To investigate the effect of dietary methyl donor intake on the risk of childhood asthma and atopy, based on the C677T polymorphism in the MTHFR gene.</p><p><strong>Methods: </strong>This cross-sectional study included 2,333 elementary school children aged 6-8 years across Korea during 2005 and 2006, as part of the first Children's Health and Environmental Research survey. Genotyping for the MTHFR (rs1801133) polymorphism was performed using the TaqMan assay. Multivariable-adjusted logistic regression analysis was performed to determine a descriptive association between the dietary methyl donor intake, MTHFR polymorphism, and childhood asthma and atopy.</p><p><strong>Results: </strong>Intake of dietary methyl donors like folates was significantly associated with a decreased risk of the wheezing symptom, in the past 12 months, and \"ever asthma\" diagnosis, respectively. Vitamin B6 intake was also associated with a decreased atopy risk. The T allele of the MTHFR (rs1801133) gene was significantly associated with a decreased risk of atopy. Increased intakes of folate, vitamin B2, and vitamin B6 were protective factors against atopy, especially in children with the T allele on the MTHFR gene, compared to those with lower intakes and the CC genotype.</p><p><strong>Conclusions: </strong>High intakes of dietary methyl donors were associated with reduced risk of atopy and asthma symptoms. These may have additive effects related to the susceptibility alleles of the MTHFR gene. The clinical implications require evaluation.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"244-253"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10452117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Level of asthma control in children and adolescents before and during the COVID-19 pandemic.","authors":"Warinda Panichaporn, Kamolthip Boonard, Kantima Kanchanapoomi, Witchaya Srisuwatchari, Orathai Jirapongsananuruk, Nualanong Visitsunthorn, Punchama Pacharn","doi":"10.12932/AP-180124-1770","DOIUrl":"10.12932/AP-180124-1770","url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, national lockdowns were implemented worldwide. Asthma control was reported to have improved. However, some patients lost follow-up from the clinic because they intended to avoid crowds at the hospital.</p><p><strong>Objective: </strong>To evaluate the level of asthma control during the COVID-19 pandemic and explore factors influencing asthma outcomes.</p><p><strong>Methods: </strong>Subjects 8-18 years old from our previous study in 2019 were recruited. The data during the pandemic period were collected between June 2021 - May 2023. The level of asthma control was compared before and during the pandemic. We also evaluated inhaled corticosteroid (ICS) adherence and factors related to poor asthma control during the COVID-19 pandemic.</p><p><strong>Results: </strong>One hundred and three subjects were enrolled. Asthma control levels remained relatively stable during the pandemic. However, an asthma exacerbation was significantly decreased from 36 (36.3%) in 2019 to 19 (19.2%)and 15 (15.1%) in 2021 and 2022 (p = 0.012, p < 0.001), respectively. Spirometry results demonstrated improved pre-bronchodilator FEV1 (89.91 ± 11.02 vs. 101.91 ± 14.11, p < 0.001). The factors related to the poor asthma outcome were not wearing a face mask (aOR = 8.52, 95%CI 1.26-57.79) and previously poor-controlled by the ACT score (aOR = 2.55, 95%CI 1.41-4.63). The median adherence rate during the pandemic was 85%. The main reasons for poor adherence were hectic lifestyle and misunderstandings of disease.</p><p><strong>Conclusion: </strong>Asthma exacerbation was significantly decreased during the lockdown. Not wearing a face mask and previously poorly controlled by the ACT score are related to poor asthma outcomes.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"312-319"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of interleukin 5-induced eosinophils in interleukin 33-triggered airway inflammation in mice.","authors":"Hitomi Tanaka, Shigeki Katoh, Kazuko Uno, Toru Oga","doi":"10.12932/AP-120821-1208","DOIUrl":"10.12932/AP-120821-1208","url":null,"abstract":"<p><strong>Background: </strong>Interleukin (IL)-5 is essential for allergen induced eosinophilic airway inflammation, but not activation of T helper type 2 (Th2) cells in the lung. Although an excessive Th2 reaction is observed without IL-5 signaling, the mechanisms have remained unknown.</p><p><strong>Objective: </strong>To evaluate the negative-feedback mechanism in eosinophilic airway inflammation, we examined IL-33 triggered eosinophilic airway inflammation in IL-5Rα-/- mice.</p><p><strong>Methods: </strong>Mice were administered intranasal IL-33 for 3 days. Airway hyperresponsiveness (AHR) was evaluated and bronchoalveolar lavage (BAL) was performed 24 h after the last IL-33 treatment. The number of inflammatory cells and cytokine levels in the BAL fluid (BALF) were analyzed, and histologic examination was performed.</p><p><strong>Results: </strong>Compared with IL-33 treated wild-type (WT) mice, intranasal administration of IL-33 in IL-5Rα-/- mice reduced eosinophilic airway inflammation, AHR, and basement membrane thickening, while we found excessive IL-33 induced IL-5 and IL-13 production in the airway without IL-5 signaling. The numbers of eosinophils with a ringshaped nucleus (resident) and segmented nucleus (inflammatory) were increased in WT mice, but not in IL-5Rα-/- mice following intranasal administration of IL-33, and the numbers of SiglecF-positive eosinophils with (resident) or without (inflammatory) expression of CD62L were also significantly increased by IL-33 treatment in WT mice, but not in IL5Rα-/- mice. The number of ILC2 cells in the BALF was significantly higher in IL-33 treated IL-5Rα-/- mice than in IL-33 treated WT mice.</p><p><strong>Conclusions: </strong>These findings suggest the possibility that IL-5 induced eosinophils contribute to the negative-feedback mechanisms in IL-33 induced ILC2 mediated airway inflammation.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"328-336"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39763039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma remission: A path to cure?","authors":"Chirawat Chiewchalermsri, Dichapong Kanjanawasee, Narongkorn Saiphoklang, Naricha Chirakalwasan, Thitiwat Sriprasart, Anchalee Senavonge, Natthawan Sanguanwong, Harutai Kamalaporn, Athipat Athipongarporn, Supitchaya Hachai, Watchara Boonsawat, John Daniel Brannan, Woo-Jung Song, Kiat Ruxrungtham, Orapan Poachanukoon","doi":"10.12932/AP-240525-2082","DOIUrl":"https://doi.org/10.12932/AP-240525-2082","url":null,"abstract":"<p><p>Asthma is a chronic inflammatory airway disease characterized by variable respiratory symptoms and reversible airflow limitation. Despite significant advances in pharmacologic and immunotherapeutic treatment, definitive remission or cure remains elusive. Asthma remission is defined as a sustained absence of symptoms, exacerbations, and lung function decline, with or without ongoing therapy. In contrast, an asthma cure implies permanent disease eradication marked by lifelong symptom resolution, no need for maintenance or rescue medication, preserved lung function, and absence of airway inflammation. To date, no intervention has been proven to cure asthma. Consequently, clinical remission has emerged as a more achievable and meaningful goal in asthma management. This review summarizes recent findings on remission rates, key factors influencing asthma remission, and the impact of various therapeutic strategies-including immunotherapy and advanced biologics. We also highlight evidence underscoring the foundational role of comprehensive asthma care. Asthma should be managed within the context of a unified allergic airway disease; thus, systematic identification and treatment of coexisting conditions such as allergic rhinitis and rhinosinusitis, nasal polyps is essential, as they often exacerbate lower airway symptoms. Routine nasal irrigation, environmental control measures, and attention to modifiable lifestyle factors-such as sleep hygiene, physical activity, and weight management-are critical. When consistently implemented, these holistic approaches may significantly improve disease control and support the achievement of clinical remission. Achieving a cure for asthma remains the ultimate goal, necessitating a long-term commitment and strategically designed basic and clinical research to determine its viability.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":"43 2","pages":"135-150"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of topical nasal steroids to improve continuous positive airway pressure compliance in patients with obstructive sleep apnea: An updated systematic review and meta-analysis of randomized control trials.","authors":"Charnsiri Segsarnviriya, Mantana Prakassajjatham, Naricha Chirakalwasan, Prakobkiat Hirunwiwatkul, Busarakum Chaitusaney, Natamon Charakorn","doi":"10.12932/AP-081122-1498","DOIUrl":"10.12932/AP-081122-1498","url":null,"abstract":"<p><strong>Background: </strong>Nasal steroids are commonly prescribed to reduce nasal side effects, which are the primary cause of continuous positive airway pressure (CPAP) intolerance in obstructive sleep apnea (OSA) patients.</p><p><strong>Objective: </strong>We conducted a systematic review and meta-analysis of OSA patients to assess the effect of nasal steroids on CPAP compliance and nasal symptoms.</p><p><strong>Methods: </strong>PubMed, Scopus, Ovid, and Cochrane Library were searched through March 2022. Randomized controlled trials (RCTs) evaluating the effects of nasal steroids on CPAP compliance in adult patients, which reported quantitative data on CPAP use and nasal symptoms, were included.</p><p><strong>Results: </strong>Three RCTs (224 patients) were eligible for the meta-analysis. At the 4-week follow-up, the study did not demonstrate a statistically significant difference in CPAP compliance (average hours of CPAP use per night: mean difference 0.45; 95% confident interval (CI) (-0.01, 0.90); P = 0.06, percentage of nights device used: mean difference 1.79; 95%CI (-2.59, 6.17); P = 0.42). There was also no difference in overall nasal symptoms (mean difference 0.47, 95%CI (-0.00, 0.94); P = 0.05), with significantly more sneezing and rhinorrhea among patients with nasal steroids (sneezing: mean difference 0.64, 95%CI (0.23, 1.05); P = 0.002, rhinorrhea: mean difference 0.78, 95%CI (0.24, 1.31); P = 0.005).</p><p><strong>Conclusions: </strong>At the 4-week follow-up, the pooled results did not demonstrate significant benefits of nasal steroids on CPAP compliance. There was also no significant benefit for relieving nasal symptoms. To further explore the benefit of nasal steroids on CPAP use, additional, longer-term studies are required.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"206-213"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical recommendations for home-nebulized corticosteroid use in children aged ≤ 5 years with asthma: A review and advisory group consensus.","authors":"Chalerat Direkwattanachai, Jitladda Deerojanawong, Chalermthai Aksilp, Orathai Jirapongsananuruk, Harutai Kamalaporn, Wasu Kamchaisatian, Sorasak Lochindarat, Lina Ngamtrakulpanit, Orapan Poachanukoon, Mongkol Lao-Araya, Jamaree Teeratakulpisarn, Kanokporn Udomittipong, Mukda Vangveeravong, Kanokpan Ruangnapa, Pantipa Chatchatee","doi":"10.12932/AP-180222-1335","DOIUrl":"10.12932/AP-180222-1335","url":null,"abstract":"<p><strong>Background: </strong>Despite nebulized budesonide being identified by the Global Initiative for Asthma report as a viable alternative to inhaled corticosteroids (ICS) delivered by pressurized metered-dose inhalers (pMDIs) with spacers, practical guidance on nebulized corticosteroid use in the pediatric population remains scarce.</p><p><strong>Objective: </strong>To review the current literature and provide practical recommendations for nebulized budesonide use in children aged ≤ 5 years with a diagnosis of asthma.</p><p><strong>Methods: </strong>A group of 15 expert pediatricians in the respiratory and allergy fields in Thailand developed Delphi consensus recommendations on nebulized budesonide use based on their clinical expertise and a review of the published literature. Studies that evaluated the efficacy (effectiveness) and/or safety of nebulized budesonide in children aged ≤ 5 years with asthma were assessed. AR patients.</p><p><strong>Results: </strong>Overall, 24 clinical studies published between 1993 and 2020 met the inclusion criteria for review. Overall, results demonstrated that nebulized budesonide significantly improved symptom control and reduced exacerbations, asthma-related hospitalizations, and the requirement for oral corticosteroids compared with placebo or active controls. Nebulized budesonide was well tolerated, with no severe or drug-related adverse events reported. Following a review of the published evidence and group consensus, a treatment algorithm as per the Thai Pediatric Asthma 2020 Guidelines was proposed, based on the availability of medications in Thailand, to include nebulized budesonide as the initial treatment option alongside ICS delivered by pMDIs with spacers in children aged ≤ 5 years.</p><p><strong>Conclusions: </strong>ThNebulized budesonide is an effective and well-tolerated treatment option in children aged ≤ 5 years with asthma.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"266-280"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9829442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent chronic spontaneous urticaria in a tropical country: Clinical characteristics and associated factors.","authors":"Pichaya Limphoka, Sukhum Jiamton, Leena Chularojanamontri, Kanokvalai Kulthanan, Papapit Tuchinda","doi":"10.12932/AP-261124-1984","DOIUrl":"https://doi.org/10.12932/AP-261124-1984","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist regarding recurrent chronic spontaneous urticaria (RCSU) following complete disease remission.</p><p><strong>Objective: </strong>This study investigated the clinical characteristics and factors associated with RCSU.</p><p><strong>Methods: </strong>We retrospectively reviewed data from chronic spontaneous urticaria (CSU) patients who actively visited the Urticaria Center of Reference and Excellence, Siriraj Hospital, between January 2021 and December 2023. Medical records were analyzed through May 2024. The RCSU was defined as a new CSU episode occurring after a 6-month symptom-free period without treatment.</p><p><strong>Results: </strong>Among 179 CSU patients, 19 (10.6%) developed RCSU. These patients had a mean age of 40 (SD 14.9) years, with a female predominance. The mean time to RCSU recurrence was 1.96 (SD 2.05) years. The UAS7 and medication scores were not significantly different between the recurrence and nonrecurrence groups (P = 0.675, P = 0.77). Multivariate analysis revealed that a shorter disease remission time from the first episode onset (< 3 years) was significantly associated with RCSU (odds ratio 5.13, 95%CI 1.83-14.29; P = 0.002).</p><p><strong>Conclusions: </strong>The RCSU rate was 10.6%. The time to disease remission from the first episode onset significantly associated with RCSU. Several clinical characteristics may corelate with the recurrence: younger age at onset, the presence of angioedema, chronic inducible urticaria comorbidity, systemic corticosteroid use, and positive antinuclear antibody status.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of patients with suspected vaccine allergies in Singapore.","authors":"Zi Teng Chai, Jia Yi Goh, Karen Jui Lin Choo, Kheng Yong Ong, Vivian Tan, Chiara Jiamin Chong, Chaw Su Naing, Haur Yueh Lee","doi":"10.12932/AP-140724-1891","DOIUrl":"https://doi.org/10.12932/AP-140724-1891","url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reaction to vaccines has been reported to occur in 5 per 100,000 doses. Although hypersensitivity reactions can occur to either the active vaccine component or other components such as excipients, outcome data from skin testing and provocation remains limited.</p><p><strong>Objective: </strong>To evaluate the role of skin testing and vaccine provocation in patients with an allergy label to vaccine.</p><p><strong>Methods: </strong>This is a single centre, prospective study between March 2021 and November 2021 of adults with known allergy to non-COVID vaccine. All participants underwent skin prick testing (SPT) and intradermal testing (IDT) to vaccine and excipients. A subset of patients with negative skin testing underwent graded vaccine provocation.</p><p><strong>Results: </strong>A total of 264 adults were evaluated. The most common index vaccine reactions were nonspecific rash (47.7%), angioedema (32.2%) and itch (25.0%). All patients had negative SPT to vaccines and excipients. Thirty patients (11.4%) had positive IDT to Hepatitis A, Hepatitis B, Human Papilloma Virus (HPV), Influenza, Measles-Mumps-Rubella (MMR), Pneumococcal, Rabies, Diphteria, Tetanus and Pertussis (DTaP). Out of 234 patients with negative IDT, 32 patients (12.1%) underwent vaccine provocation. Three patients (9.4%) developed reaction to influenza and MMR vaccine. One patient required systemic corticosteroids, one required antihistamine, and another patient did not require any treatment. None required admission or attendance at emergency department.</p><p><strong>Conclusions: </strong>The majority of allergy labels to vaccine are inaccurate based on low skin test positivity and low reaction rates on vaccine provocation. Vaccine provocation is safe. Excipients are unlikely to be the main cause of hypersensitivity reactions in vaccines.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgE-sensitization and cross-reactivity of Der f 23 and Der p 23 in Korean patients with allergy.","authors":"Myung-Hee Yi, Tai-Soon Yong, Chung-Ryul Kim, Kyoung Yong Jeong, Ju Yeong Kim","doi":"10.12932/AP-120924-1924","DOIUrl":"https://doi.org/10.12932/AP-120924-1924","url":null,"abstract":"<p><strong>Background: </strong>House dust mites (HDM) are a major source of allergens, and more than 30 HDM allergens have been identified to date. Recently, Der p 23 was reported to be a major allergen that is related to the severity of allergic responses.</p><p><strong>Objective: </strong>This study aimed to characterize IgE-sensitization and cross-reactivity between Der f 23 and Der p 23 in Korean patients with allergy.</p><p><strong>Methods: </strong>We produced recombinant Der f 23 and Der p 23 using a yeast Pichia expression system. The IgE binding activity of Der f 23 and Der p 23 was evaluated by enzyme-linked immunosorbent assay (ELISA) using sera from 194 Korean HDM-sensitized patients. The cross-reactivity between Der f 23 and Der p 23 was then assayed using competitive ELISA.</p><p><strong>Results: </strong>Among the 194 HDM-allergic patients, IgE reactivity to rDer f 23 and rDer p 23 was observed in 45.36% (88/194) and 43.81% (85/194) of the samples, respectively. Competitive ELISA with pooled serum from 10 patients revealed that rDer p 23 inhibited 86.1% of the rDer f 23 IgE reactivity and rDer f 23 inhibited 61.1% of the rDer p 23 IgE reactivity.</p><p><strong>Conclusions: </strong>Group 23 HDM allergens, Der f 23 and Der p 23, show moderate sensitization, with 45.36% and 43.81% of Korean patients with allergy reacting to them, respectively. Significant IgE cross-reactivity was observed between the two allergens. These findings can facilitate the development of component-resolved diagnosis and allergen-specific immunotherapy in the future.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}